EMERALD Expert Views: Managing ER+/HER2-, ESR1m mBC Disease Progression Post ET+CDK4/6i

Medical Industry Feature

Host: Jennifer Caudle, DO
Guest: Virginia Kaklamani, MD
Guest: Anne O'Dea, MD
When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there’s uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU^® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,¹ contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.